Skip to main content
SpringerLink
Log in

Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions

  • Published:
Journal of Gastrointestinal Surgery

Abstract

In clinical practice it is important to differentiate pseudocysts from cystic pancreatic tumors, especially potentially malignant mucinous cystic tumors. We investigated three new markers—tumor-associated trypsin inhibitor (TATI) and the free α and β subunits of human choriogonadotropin (hCGα and hCGβ, respectively)—in the cyst.uid of patients with cystic pancreatic lesions and compared the concentrations of these markers to those of carcinoembryonic antigen (CEA), CA 19-9, CA 242, CA 125, CA 15-3, alpha-fetoprotein, and tissue polypeptide antigen in order to distinguish benign cysts from malignant cysts. Between 1995 and 2001, a total of 34 patients operated on for cystic pancreatic lesions at Tampere University Hospital were included. Cyst fluid was aspirated at operation and stored at_70 C. Thehistologic diagnosis was pseudocyst in 23 patients, serous cystadenoma (SCA) in four patients, benign mucinous cystadenoma (MCA) in four patients, cystic papillary neoplasm (CPN) in one patient, glucagonoma in one patient, and malignant endocrine islet cell carcinoma (EC) in one patient. Significantly higher concentrations of TATI were found in patients with MCA and EC (2239 ± 149 μg/L [mean ± SEM]) than in patients with pseudocyst (55 ± 29 μg/L; P = 0.001) and in patients with SCA (36 ± 23 μg/L; P = 0.01). The patient with CPN and the patient with glucagonoma had relatively low levels of TATI (30.7 and 46.5 μg/L). Mean CEA was higher in patients with MCA compared to those with pseudocysts (19,993 ± 9418 vs. 53 ± 20 μg/L, P = 0.002) and SCA (0.4 ± 0.1 μg/L; P = 0.02), but in the patient with malignant EC, the patient with CPN, and the patient with glucagonoma, CEA was normal. HCGα, hCGβ, CA 19-9, CA 242, CA 125, CA 15-3, alpha fetoprotein, and tissue polypeptide antigen could not distinguish between MCA vs. pseudocyst or SCA, because both normal and elevated values were seen in all groups. To our knowledge, this is the first time that TATI has been quantitated in the cyst fluid of patients with cystic pancreatic lesions. It appears to be a potential marker in the differential diagnosis of benign from malignant cystic pancreatic lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hoover E, Natesha R, Dao A, Adams CZ, Barnwell S. Proliferative pancreatic cysts: Pathogenesis and treatment options. Am J Surg 1991;162:274–277.

    Article  PubMed  CAS  Google Scholar 

  2. Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen rich cystadenomas): A clinicopathologic study of 34 cases. Am J Clin Pathol 1978;69:289–298.

    PubMed  CAS  Google Scholar 

  3. Sand J, Hyoty M, Mattila J, Dagorn JC, Nordback I. Clinical assessment compared with cyst fluid analysis in the differential diagnosis of cystic lesions in the pancreas. Surgery 1996; 119:275–280.

    Article  PubMed  CAS  Google Scholar 

  4. Warshaw AL, Compton CC, Lewandorwski K, Cardenosa G, Mueller PR. Cystic tumors of the pancreas—New clinical, radiological, and pathologic observations in 67 patients. Ann Surg 1990;212:432–443.

    Article  PubMed  CAS  Google Scholar 

  5. Sperti C, Pasquali C, Di Prima F, Rugge M, Petrin P, Costantino V, Canton A, Pedrazzoli S. Percutaneous CT-guided fine-needle aspiration cytology in the differential diagnosis of pancreatic lesions. Ital J Gastroenterol 1994;26:126–131.

    PubMed  CAS  Google Scholar 

  6. Stenman UH, Koivunen E, Itkonen O. Biology and function of tumor-associated trypsin inhibitor. Scand J Clin Lab Invest Suppl 1991;207:5–9.

    PubMed  CAS  Google Scholar 

  7. Gadducci A, Ferdeghini M, Prontera C, Moretti L, Mariani L, Mariani G, Bianchi R, Fioretti P. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: Relevance for differential diagnosis. Gynecol Oncol 1992;44:147–154.

    Article  PubMed  CAS  Google Scholar 

  8. Lukkonen A, Lintula S, von Boguslawski K, Carpen O, Ljungberg B, Landberg G, Stenman UH. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer 1999;83:486–490.

    Article  PubMed  CAS  Google Scholar 

  9. Stenman UH. Tumor-associated trypsin inhibitor. Clin Chem 2002;48:1206–1209.

    PubMed  CAS  Google Scholar 

  10. Pectasides D, Bafaloucos D, Antoniou F, Gogou L, Economides N, Varthalitis J, Dimitriades M, Kosmidis P, Athanassiou A. TPA, TATI, CEA, AFP, beta-HCG, PSA, SCC and CA 19-9 monitoring transitional cell carcinoma of the bladder. Am J Clin Oncol 1996;19:271–277.

    Article  PubMed  CAS  Google Scholar 

  11. Haglund C, Huhtala ML, Halila H, Nordling S, Roberts PJ, Scheinin TM, Stenman U. Tumor-associated trypsin inhibitor, TATI, in patients with pancreatic cancer, pancreatitis and benign biliary diseases. Br J Cancer 1986;54:297–303.

    PubMed  CAS  Google Scholar 

  12. Masson P, Palsson B, Andren-Sandberg Å. Evaluation of CEA, CA 19-9, CA-50, CA-195 and TATI with special reference to pancreatic disorders. Int J Pancreatol 1991;8:333–344.

    PubMed  CAS  Google Scholar 

  13. Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Tumor-associated trypsin inhibitor in the diagnosis of pancreatic carcinoma. J Cancer Res Clin Oncol 1994;120:494–497.

    Article  PubMed  CAS  Google Scholar 

  14. Hedström J, Haglund C, Leinonen J, Nordling S, Stenman UH. Trypsinogen-1, -2 and tumor-associated trypsin-inhibitor in bile and biliary tract tissues from patients with biliary tract diseases and pancreatic carcinomas. Scand J Clin Lab Invest 2001;61:111–118.

    Article  PubMed  Google Scholar 

  15. Marcillac I, Troalen F, Bidart JM, Ghillani P, Ribrag V, Escudier B, et al. Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res 1992;52:3901–3907.

    PubMed  CAS  Google Scholar 

  16. Lundin M, Nordling S, Carpelan-Holmström M, Louhimo J, Alfthan H, Stenman UH, Haglund C. A comparison of serum and tissue hCG beta as prognostic markers in colorectal cancer. Anticancer Res 2000;20:4949–4951.

    PubMed  CAS  Google Scholar 

  17. Vartiainen J, Lehtovirta P, Finne P, Stenman UH, Alfthan H. Preoperative serum concentration of hCGbeta as a prognostic factor in ovarian cancer. Int J Cancer 2001;95:313–316.

    Article  PubMed  CAS  Google Scholar 

  18. Louhimo J, Finne P, Alfthan H, Stenman UH, Haglund C. Combination of hCGbeta, CA 19-9 and CEA with logistic regression improves accuracy in gastrointestinal malignancies. Anticancer Res 2002;22:1759–1764.

    PubMed  CAS  Google Scholar 

  19. Louhimo J, Nordling S, Alfthan H, von Boguslawski K, Stenman UH, Haglund C. Specific staining of human chorionic gonadotropin beta in benign and malignant gastrointestinal tissues with monoclonal antibodies. Histopathology 2001;38:418–424.

    Article  PubMed  CAS  Google Scholar 

  20. Syrigos KN, Fyssas I, Konstandoukalis MM, Harrington KJ, Papadopoulos S, Milimgos N, Peveretos P, Golematis BC. Beta human chorionic gonadotropin concentrations in serum patients with pancreatic adenocarcinoma. Gut 1998; 42:88–91.

    Article  PubMed  CAS  Google Scholar 

  21. Grossmann M, Trautmann ME, Poertl S, Hoermann R, Berger P, Arnold R, Mann K. Alpha-subunit and human chorionic gonadotropin-beta immunoreactivity in patients with malignant endocrine gastroenteropancreatic tumors. Eur J Clin Invest 1994;24:131–136.

    Article  PubMed  CAS  Google Scholar 

  22. Alfthan H, Schroder J, Fraser R, Koskimies A, Halila H, Stenman UH. Choriogonadotropin and its beta subunit separated by hydrophobic-interaction chromatography and quantified in serum during pregnancy by time-resolved immunofiuorometric assays. Clin Chem 1988;34:1758–1762.

    PubMed  CAS  Google Scholar 

  23. Stenman UH, Huhtala ML, Koistinen R, Seppälä M. Immunochemical demonstration of an ovarian cancer-associated urinary peptide. Int J Cancer 1982;30:53–57.

    Article  PubMed  CAS  Google Scholar 

  24. Huhtala ML, Pesonen K, Kalkkinen N, Stenman UH. Purication and characterisation of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem 1982;257:13713–13716.

    PubMed  CAS  Google Scholar 

  25. Satake K, Inui A, Sogabe T, Yoshii Y, Nakata B, Tanaka H, Chung YS, Hiura A, Umeyama K. The measurement of serum immunoreactive pancreatic trypsin inhibitor in gastrointestinal cancer and pancreatic disease. Int J Pancreatol 1988; 3:323–331.

    PubMed  CAS  Google Scholar 

  26. Sarr M, Murr M, Smyrk T, Yeo C, Fernandez-del-Castillo C, Hawes R, Freeny P. Primary cystic neoplasms of the pancreas: Neoplastic disorders of emerging importance-Current state-of-art and unanswered questions. J GASTROINTEST SURG 2003;7:417–428.

    Article  PubMed  Google Scholar 

  27. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994;178:187–211.

    PubMed  CAS  Google Scholar 

  28. Lomsky R, Langr F, Vortel V. Demonstration of glucagon in islet cell adenomas of the pancreas by immunofiuorescent technique. Am J Clin Pathol 1969;51:245–250.

    PubMed  CAS  Google Scholar 

  29. Martin RC, Klimstra DS, Brennan MF, Conlon KC. Solidpseudopapillary tumor of the pancreas: A surgical enigma. Ann Surg Oncol 2002;9:35–40.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Tampere University Hospital, P.O. Box 2000, FIN-33521, Tampere, Finland

    Sari Räty M.D., Juhani Sand M.D. & Isto Nordback M.D.

  2. Departments of Clinical Chemistry, Helsinki University Hospital, Helsinki, Finland

    Henrik Alfthan Ph.D.

  3. Departments of Surgery, Helsinki University Hospital, Helsinki, Finland

    Caj Haglund M.D.

Authors
  1. Sari Räty M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Juhani Sand M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Henrik Alfthan Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caj Haglund M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Isto Nordback M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sari Räty M.D..

Additional information

Supported by the Medical Research Fund of Tampere University Hospital.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Räty, S., Sand, J., Alfthan, H. et al. Cyst fluid tumor-associated trypsin inhibitor may be helpful in the differentiation of cystic pancreatic lesions. J Gastrointest Surg 8, 569–574 (2004). https://doi.org/10.1016/j.gassur.2004.01.005

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.gassur.2004.01.005

Key words

Search

Navigation